Triamcinolone acetonide in the treatment of corticosteroid-resistant asthma: Risks and benefits;Acetónido de triamcinolona en el tratamiento del asma resistente a los glucocorticoides: Riesgos y beneficios

Archivos de Bronconeumologia

Volumn 44, Issue 6, 2008, Pages 324-327

  Picado, César ^a,b   Vennera, María Del Carmen ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Corticosteroid resistant asthma; Prednisone; Severe asthma; Triamcinolone acetonide

Indexed keywords

PREDNISONE; TRIAMCINOLONE ACETONIDE;

ASTHMA; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG EFFICACY; DRUG USE; HUMAN; REVIEW; RISK; RISK BENEFIT ANALYSIS; SKIN DEFECT;

EID: 48249111396     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1157/13123090     Document Type: Review

References (22)

1. ERS Task Force on Difficult/Therapy-Resistant Asthma. Difficult/therapy-resistant asthma: the need for an integrated approach to define clinical phenotypes, evaluate risk factors, understand pathophysiology and find novel therapies. Eur Respir J. 1999;13:1198-208.
2. Cosío BG, Torrego A, Adcock IM. Mecanismos moleculares de los glucocorticoides. Arch Bronconeumol. 2005;41:34-41.
3. Pujols L, Mullol J, Torrego A, Picado C. Glucocorticoid receptors in human airways. Allergy. 2004;59:1042-52.
4. López-Viña A, Agüero-Balbín R, Aller-Álvarez JL, Bazús-González T, Cosío BG, De Diego-Damián A, et al. Normativa para el asma de difícil control. Arch Bronconeumol. 2005;41:513-23.
5. Cabrera-Navarro P. Antiinmunoglobulina E, un anticuerpo monoclonal, en el tratamiento de las enfermedades respiratorias. Arch Bronconeumol. 2006;42:241-5.
6. Peake MD, Cayton RM, Howard P. Triamcinolone in corticosteroid-resistant asthma. Br J Dis Chest. 1979;73:39-44.
7. Panickar JR, Kenia P, Silverman M, Grigg J. Intramuscular triamcinolone for difficult asthma. Pediatric Pulmonol. 2005:39:421-5.
8. Panickar JR, Bhatnagar N, Grigg J. Exhaled nitric oxide after a single dose of intramuscular triamcinolone in children with difficult to control asthma. Pediatric Pulmonol. 2007;42:573-8.
9. Ogirala RG, Sturm TM, Aldrich TK, Meller FF, Pacia EB, Keane AM, et al. Single, high-dose intramuscular triamcinolone acetonide versus weekly oral methotrexate in life-threatening asthma: a double-blind study. Am J Respir Crit Care Med. 1995;152:1461-6.
10. McLeod DT, Capewell SJ, Law J, MacLaren W, Seaton A. Intramuscular triamcinolone acetonide in chronic severe asthma. Thorax. 1985;40:840-5.
11. Willey RF, Fergusson RJ, Godden DJ, Crompton GK, Grant IW. Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma. Thorax. 1984;39:340-4.
12. Ten Brinke A, Zwinderman AH, Sterk PJ, Rabe KF, Bel EH. "Refractory" eosinophilic airway inflammation in severe asthma: effect of parenteral corticosteroids. Am J Respir Cir Care Med. 2004;170:601-5.
13. Mancinelli L, Navarro L, Sharma OP. Intramuscular high-dose triamcinolone acetonide in the treatment of severe chronic asthma. West J Med. 1997;167:322-9.
14. Ogirala RG, Aldrich TK, Prezant DJ, Sinnett MJ, Enden JB, Williams MH Jr. High-dose intramuscular triamcinolone in severe, chronic, life-threatening asthma. N Engl J Med. 1991;324:585-9.
15. Cunnington D, Smith N, Steed K, Rosengarten P, Kelly AM, Teichtahl H. Oral versus intravenous corticosteroids in adults hospitalised with acute asthma. Pulm Pharmacol Ther. 2005;18:207-12.
16. Becker JM, Arora A, Scarfone RJ, Spector ND, Fontana-Penn ME, Gracely E, et al. Oral versus intravenous corticosteroids in children hospitalized with asthma. J Allergy Clin Immunol. 1999;103:586-90.
17. Kusama M, Sakauchi N, Kumaoka S. Studies of plasma levels and urinary excretion after intramuscular injection of triamcinolone acetonide. Metabolism. 1971:20:590-6.
18. Prednisone metabolism. En: Hardman JG, Limbird LE, editors. Goodman and Gilman's. The pharmacological basis of therapeutics. New York: McGraw-Hill; 2001. p. 1987.
19. Boushey HA. Treatment of chronic severe asthma. West J Med. 1997;157:359-60.
20. Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15:406-20.
21. Heuck C, Wolthers OD, Hansen M, Kollerup G. Short-term growth and collagen turnover in asthmatic adolescents treated with the inhaled glucocorticoid budesonide. Steroids. 1997;62:659-64.
22. Zein WM, Noureddin BN, Jurdi FA, Schakal A, Bashshur ZF. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina. 2006;26:137-42.